A phase 1 study of the c-Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111)

  • James I. Geller
  • , John P. Perentesis
  • , Xiaowei Liu
  • , Charles G. Minard
  • , Rachel A. Kudgus
  • , Joel M. Reid
  • , Elizabeth Fox
  • , Susan M. Blaney
  • , Brenda J. Weigel

Research output: Contribution to journal › Article › peer-review

13   Link opens in a new tab Scopus citations

Fingerprint

Dive into the research topics of 'A phase 1 study of the c-Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111)'. Together they form a unique fingerprint.
Sort by

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science